Piramal Pharma Limited Announces Results for Q4 and FY2025

      Key Highlights for Q4FY25/FY25 Nandini Piramal, Chairperson, Piramal Pharma Limitedsaid, " FY25 has been a steady year for the company as we crossed$1Bnin revenues with 12% YoY growth accompanied by 17% EBITDA margin and 5x increase in Net Profits, in-line with our annual guidance. We also managed to maintain our Net Debt / EBITDA level below 3x, while making regular investments in capabilities and capacities for future growth. During the year, we progressed well on our...

MUMBAI, India, 14/05/2025 (informazione.news - comunicati stampa - salute e benessere)

 

 

said, "

 

-  - Grew by over 50% YoY to reach $179mn (Vs. $116mn in FY24 and $53mn in FY23)

-  Revenues from grew 28% YoY, contributing to 49% of CDMO revenues

-  Healthy growth in

-  driven by better procurement strategies, cost optimization and operational excellence initiatives

-  - Successfully cleared 36 regulatory inspections and 165 customer audits in FY25 without any major observations

 

-  - Major GPO contract renewal and order wins supporting IA sales in the US. Witnessing encouraging traction in the RoW markets

-  in India completed and commercialized on time; poised to capitalize on in the RoW markets

-  in the US in Sevoflurane (44% market share ) and in intrathecal Baclofen (75% market share )

-   Received for multiple markets in EU and UK by our partner BrePco Pharma. Neoatricon® is the only pre-diluted, age-appropriate formulation of dopamine, approved for treating children and infants

-  Moderation in EBITDA margins due to some non-recurring expenses and capacity expansion in India. However, recovery expected from FY26 with commercialization of these added capacities

 

-  ICH business crossed the during the year

-  continue to grow strength to strength with 20% YoY during FY25. Power Brands contributed to 49% of total ICH sales

o  Excluding i-range, which was impacted by regulatory price control, growth in power brands was about 26% in FY25

-  - Added 21 new products and 31 new SKUs in FY25

-  11% of ICH sales in FY25. Launched our new media campaign with Yami Gautam for Little's

-  sales grew at 39% YoY in FY25, contributing 21% to ICH sales,. Present on more than 20 e-commerce platforms

 

 

 

 

 

 

 

Piramal Pharma Limited will be hosting a conference call for investors / analysts on

The dial-in details for the call are as under:

 

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

* Includes one facility via PPL's minority investment in Yapan Bio.

For more information, visit: Piramal Pharma | LinkedIn

Logo - https://mma.prnewswire.com/media/1855206/4913155/Piramal_Pharma_Limited_Logo.jpg

 

 

                      

View original content:https://www.prnewswire.co.uk/news-releases/piramal-pharma-limited-announces-results-for-q4-and-fy2025-302455718.html